Related Experiment Video
Updated: Mar 10, 2026

Detecting Estrogenic Ligands in Personal Care Products using a Yeast Estrogen Screen Optimized for the Undergraduate Teaching Laboratory
Published on: January 1, 2018
From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs" Using Novel Combinations
Maytham H Hussein1, Elena K Schneider1, Alysha G Elliott2
11 Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University , Parkville, Australia .
Abstract:
Novel therapeutic approaches are urgently needed to combat nosocomial infections caused by extremely drug-resistant (XDR) "superbugs." This study aimed to investigate the synergistic antibacterial activity of polymyxin B in combination with selective estrogen receptor modulators (SERMs) against problematic Gram-negative pathogens. In vitro synergistic antibacterial activity of polymyxin B and the SERMs tamoxifen, raloxifene, and toremifene was assessed using the microdilution checkerboard and static time-kill assays against a panel of Gram-negative isolates. Polymyxin B and the SERMs were ineffective when used as monotherapy against polymyxin-resistant minimum inhibitory concentration ([MIC] ≥8 mg/L) Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii. However, when used in combination, clinically relevant concentrations of polymyxin B and SERMs displayed synergistic killing against the polymyxin-resistant P. aeruginosa, K. pneumoniae, and A. baumannii isolates as demonstrated by a ≥2-3 log10 decrease in bacterial count (CFU/ml) after 24 hours. The combination of polymyxin B with toremifene demonstrated very potent antibacterial activity against P. aeruginosa biofilms in an artificial sputum media assay. Moreover, polymyxin B combined with toremifene synergistically induced cytosolic green fluorescence protein release, cytoplasmic membrane depolarization, permeabilizing activity in a nitrocefin assay, and an increase of cellular reactive oxygen species from P. aeruginosa cells. In addition, scanning and transmission electron micrographs showed that polymyxin B in combination with toremifene causes distinctive damage to the outer membrane of P. aeruginosa cells, compared with treatments with each compound per se. In conclusion, the combination of polymyxin B and SERMs illustrated a synergistic activity against XDR Gram-negative pathogens, including highly polymyxin-resistant P. aeruginosa isolates, and represents a novel combination therapy strategy for the treatment of infections because of problematic XDR Gram-negative pathogens.
Insights
Novel therapies combining polymyxin B with selective estrogen receptor modulators (SERMs) show synergistic antibacterial activity against extremely drug-resistant Gram-negative pathogens. This combination offers a promising strategy for treating infections caused by these challenging "superbugs".
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Background:
- Extremely drug-resistant (XDR) Gram-negative pathogens, or "superbugs," pose a significant threat, necessitating novel therapeutic strategies.
- Polymyxin B is a last-resort antibiotic, but resistance is increasing, limiting its clinical utility.
- Selective estrogen receptor modulators (SERMs) have not been extensively explored for their direct antibacterial properties or synergistic potential.
Purpose of the Study:
- To investigate the synergistic antibacterial activity of polymyxin B in combination with SERMs against problematic Gram-negative pathogens.
- To evaluate the efficacy of this combination against polymyxin-resistant isolates of Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter baumannii.
Main Methods:
- In vitro assessment of synergistic activity using microdilution checkerboard and static time-kill assays.
- Evaluation of bacterial killing, biofilm inhibition, membrane depolarization, and reactive oxygen species generation.
- Microscopic analysis (scanning and transmission electron microscopy) to observe cellular damage.
Main Results:
- Polymyxin B and SERMs (tamoxifen, raloxifene, toremifene) were ineffective as monotherapy against polymyxin-resistant Gram-negative bacteria.
- Combination therapy demonstrated synergistic killing, reducing bacterial counts by ≥2-3 log10 CFU/ml after 24 hours.
- Polymyxin B with toremifene showed potent activity against P. aeruginosa biofilms and induced significant membrane damage and cellular stress.
Conclusions:
- The combination of polymyxin B and SERMs exhibits significant synergistic activity against XDR Gram-negative pathogens, including polymyxin-resistant strains.
- This novel combination therapy strategy holds promise for treating infections caused by difficult-to-treat Gram-negative bacteria.
- Further research into this combination could lead to new treatment options for nosocomial infections.
More Related Videos
08:19Generating Transposon Insertion Libraries in Gram-Negative Bacteria for High-Throughput Sequencing
Published on: July 7, 2020
06:18An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Related Concept Videos
Development of Antibiotic Resistance
Antimicrobial Effectiveness
Gene Regulation in Microbial Communities: Quorum Sensing
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Antibiotic Selection
Combined Effects of Drugs: Synergism
Such synergistic combinations...